Understanding Telmisartan (CAS No. 144701-48-4): A Key Antihypertensive Agent
Telmisartan, identified by its Chemical Abstracts Service (CAS) number 144701-48-4, is a well-established pharmaceutical compound widely used in the management of hypertension and related cardiovascular conditions. It belongs to a class of drugs known as angiotensin II receptor blockers (ARBs), which are central to modern approaches for controlling high blood pressure and preventing cardiovascular complications.
Chemical and Physical Characteristics
Telmisartan is chemically classified as a benzimidazole derivative. Its molecular formula is C33H30N4O2, and it has a molecular weight of approximately 514.6 g/mol. The compound appears as a white to slightly yellowish crystalline powder, practically insoluble in water but more soluble in organic solvents such as methanol and dimethyl sulfoxide (DMSO). This limited aqueous solubility presents a formulation challenge, often addressed through innovative drug delivery systems to enhance bioavailability.
Structurally, Telmisartan contains two benzimidazole rings linked to a biphenyl moiety, contributing to its high receptor affinity and selectivity for the angiotensin II type 1 (AT1) receptor. Its chemical stability and lipophilicity allow for a prolonged duration of action, which supports once-daily dosing.
Mechanism of Action
Telmisartan functions as a selective antagonist of the angiotensin II type 1 (AT1) receptor. Angiotensin II is a potent vasoconstrictor that plays a critical role in regulating blood pressure, fluid balance, and vascular tone. By blocking the binding of angiotensin II to the AT1 receptor, Telmisartan prevents vasoconstriction and the secretion of aldosterone — a hormone responsible for sodium and water retention.
This dual action results in vasodilation, decreased blood volume, and a reduction in systemic blood pressure. Importantly, Telmisartan does not inhibit the angiotensin-converting enzyme (ACE), which means it does not interfere with bradykinin metabolism. As a result, Telmisartan is less likely to cause side effects such as persistent cough or angioedema, which are sometimes observed with ACE inhibitors.
Pharmacokinetics and Metabolism
After oral administration, Telmisartan exhibits an absolute bioavailability of approximately 40–60%, depending on the formulation. It reaches peak plasma concentration within 0.5 to 1 hour. The compound is highly bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein, which contributes to its long half-life of around 24 hours.
Telmisartan undergoes minimal metabolism in the liver, primarily via glucuronidation rather than oxidation. It is excreted mainly in the feces as unchanged drug, with less than 1% eliminated via the kidneys. This metabolic profile makes Telmisartan suitable for patients with mild to moderate renal impairment, as dosage adjustments are typically unnecessary.
Therapeutic Applications
The primary indication for Telmisartan is the management of hypertension. By lowering blood pressure, it significantly reduces the risk of stroke, myocardial infarction, and other cardiovascular events. Beyond its antihypertensive role, Telmisartan has demonstrated protective effects in cardiovascular and metabolic disorders, including:
- Heart failure (as part of combination therapy)
- Diabetic nephropathy and chronic kidney disease
- Metabolic syndrome, due to its favorable effects on insulin sensitivity and lipid metabolism
Some studies have also explored the pleiotropic effects of Telmisartan, suggesting that its activation of peroxisome proliferator-activated receptor-gamma (PPAR-γ) may contribute to improved glucose metabolism and endothelial function.
Safety Profile and Tolerability
Telmisartan is generally well-tolerated, with a low incidence of adverse effects. The most common side effects include dizziness, fatigue, and mild gastrointestinal disturbances. Unlike ACE inhibitors, Telmisartan rarely causes dry cough or angioedema. It is contraindicated in pregnancy due to the risk of fetal toxicity associated with drugs acting on the renin-angiotensin system.
Patients with severe hepatic impairment should use Telmisartan with caution, as liver function affects its elimination. Additionally, combining Telmisartan with potassium-sparing diuretics or potassium supplements should be monitored to avoid hyperkalemia.
Future Perspectives
Research continues to explore the broader therapeutic potential of Telmisartan beyond hypertension. Its unique pharmacological properties, including PPAR-γ activation and endothelial protection, open new avenues for its use in metabolic and inflammatory disorders. Moreover, formulation advancements — such as nanocarrier-based delivery and solid dispersions — are being developed to enhance its solubility and bioavailability.
Conclusion
Telmisartan (CAS No. 144701-48-4) stands as a cornerstone in antihypertensive therapy, offering efficacy, safety, and metabolic benefits. Its selective blockade of the angiotensin II receptor provides robust blood pressure control with a favorable side-effect profile. Ongoing research continues to expand our understanding of its potential applications, ensuring that Telmisartan remains a vital component of cardiovascular and metabolic health management.
URL: For more information, visit Verdant Pharma : CAS NO 144701-48-4 (TELMISARTAN)